xtremepicks.com: www.Xtremepicks.Com: Xtremepicks Alerts November 5, 2009 : MNDO, CLDX, DELL and MITI

Xtremepicks.com Alerts include MIND C.T.I. LTD. (NASDAQ: MNDO), Celldex Therapeutics, Inc. (Nasdaq: CLDX), Dell (NASDAQ: DELL) and Micromet, Inc. (Nasdaq: MITI)

MIND C.T.I. LTD. (NASDAQ: MNDO) trading at $1.54 on a volume of 10,850 shares

In a press release out on November 5, MIND CTI Reports Results for the Third Quarter 2009

*Cash Flow From Operating Activities of $1.6 Million

*MIND to Delist From TASE

YOQNEAM, ISRAEL, Nov 05, 2009 -- MIND C.T.I. LTD. (NASDAQ: MNDO), a leading provider of convergent end-to-end billing and customer care product based solutions for service providers as well as telecom expense management (call management) solutions, today announced results for the third quarter 2009 and that its Board of Directors has resolved to delist the Company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE).

About MIND

MIND CTI Ltd. is a leading provider of convergent end-to-end billing and customer care product based solutions for service providers as well as telecom expense management (call management) solutions. MIND provides a complete range of billing applications for any business model (license, managed service or complete outsourced billing service) for Wireless, Wireline, VoIP and Quad-play carriers in more than 40 countries around the world.

Celldex Therapeutics, Inc. (Nasdaq: CLDX) trading at $4.92 per share on trading volume of 135,596 shares.

In a press release out on November 5, Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009

NEEDHAM, Mass., Nov 05, 2009 -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at Merriman Curhan Ford's 6th Annual Investor Summit at the Sofitel Hotel, New York City on Tuesday, November 10, 2009 at 2:40 pm, EST.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. For more information, please visithttp://www.celldextherapeutics.com.

Dell (NASDAQ:DELL) trading at $14.77 on a volume of 5.62M shares

In a press release out on November 5, Dell Announces Adamo XPS, A Dazzling Gift Idea for Style-Minded This Holiday Season

World's Thinnest Laptop is 0.4-inch thin

ROUND ROCK, Texas, Nov 05, 2009 -- --Adamo XPS Reinforces Dell's Commitment to Craftsmanship and Design

--Advanced Head-Turning Design Offers Full Feature Set for On-The-Go Computing Last spring Dell (NASDAQ:DELL) set the computing industry abuzz with the introduction of its Adamo brand, and along with it the world's thinnest laptop PC. Today, the world meets a new champion of thin: The Dell(TM) Adamo XPS(TM), measuring 9.99mm or just four-tenths of an inch. Both laptops set new standards for craftsmanship, design and engineering excellence.

About Dell

People worldwide can buy Dell online, by phone and in more than 43,000 stores.

Micromet, Inc. (Nasdaq:MITI) trading at $5.30 on a volume of 83,771 shares

In a press release out on November 5, Micromet, Inc. Replay of Third Quarter 2009 Financial Results Conference Call Now Available

BETHESDA, Md., Nov 5, 2009 -- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announces that a replay of the Third Quarter 2009 Financial Results conference call is now immediately available.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include sanofi-aventis, Bayer Schering Pharma, Merck Serono, Nycomed and MedImmune.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: billing, business, cancer, ceo, clinical, conference, disease, email, e-mail, engineering, financial results, health, hotel, investment, investment opinion, israel, nasdaq, new york, online, pipeline, president, product development, products, profit, technology, telecom, texas, web, wireless, wireline